Key statistics
As of last trade Royalty Pharma PLC (RPRX:NSQ) traded at 43.79, -2.54% below its 52-week high of 44.93, set on Feb 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 44.64 |
|---|---|
| High | 44.90 |
| Low | 43.63 |
| Bid | 43.78 |
| Offer | 43.79 |
| Previous close | 44.05 |
| Average volume | 3.90m |
|---|---|
| Shares outstanding | 577.24m |
| Free float | 387.93m |
| P/E (TTM) | 25.19 |
| Market cap | 25.43bn USD |
| EPS (TTM) | 1.75 USD |
| Annual div (ADY) | 0.94 USD |
|---|---|
| Annual div yield (ADY) | 2.13% |
| Div ex-date | Nov 14 2025 |
| Div pay-date | Dec 10 2025 |
| Next div ex-date | Feb 20 2026 |
| Next div pay-date | Mar 10 2026 |
Data delayed at least 15 minutes, as of Feb 10 2026 17:24 GMT.
More ▼
- Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
- Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
- Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports Third Quarter 2025 Results
- Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
More ▼
